Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > Orphan in need of adoption

Nano therapy for ovarian cancer will enable superior tumor accumulation and retention of radioactivity, resulting in better therapuetic efficacy than existing standards of care.

Orphan in need of adoption

Philadelphia, PA | Posted on December 8th, 2006

Twenty thousand new cases of ovarian cancer are diagnosed in the United States each year. More than 75% of these patients are women with late stage ovarian cancer. The prognosis for this group is very poor: only 30% will survive five years or longer.

Even treatment for ovarian cancer can be devastating to a patient's quality of life. Treatment commonly involves invasive surgery followed by extensive chemotherapy, both of which can be physically and emotionally traumatic.

Under funding received from The Nanotechnology Institute and the National Cancer Institute, University of Pennsylvania Scientists have created a nanotechnology-based radiopharmaceutical that could potentially improve the treatment of ovarian cancer.

The proprietary platform technology specifically targets cancer cells via the folate receptor pathway, minimizing damage to surrounding non-cancerous cells. In principle, the drug will enable a higher tumor radiation dose than is possible with other radiotherapeutics, which do not deliver enough radiation to be useful for treatment.

Unfortunately, despite tremendous laboratory progress, this technology may never reach the patients who need it most. The reason is that the market opportunity for ovarian cancer is small (~$75M/year) - too small to justify development by a large multinational corporation.

"This is a platform technology with enormous potential, but its early stage means there is also enormous clinical risk," says Dr. Brian Smith, a co-inventor of the technology. "Our work with Greg Adams at the Fox Chase Cancer Center is promising, but it suggests the need for additional experiments."

Usually at this stage of development, a sponsoring company would invest and work with the scientist to further the research. However, the small market size is a significant barrier to attracting would-be investors. Dr. Smith also hopes to keep the drug affordable, launching at a price of around $5,000 instead of the $50,000 that could be charged for this type of therapy.

"What we need is an angel with personal interest," says Hugo Fitzgerald, Manager of Nanotechnology and Licensing at the University of Pennsylvania. "We have an adequate IP portfolio to justify the creation of a small start up, what we lack is the outside management to champion it and push it out of the laboratory and into the FDA approval process."

The therapeutic would likely qualify for tax credits and marketing exclusivity under the Orphan Drug Act, priority FDA review, and accelerated FDA approval. Follow on applications could include treatments for various other cancers as well as a related radiopharmaceutical for diagnostic imaging.

If interested in working with or supporting the research, please contact:

Hugo FitzGerald
Manager Nanotechnology and Licensing
Center for Technology Transfer
University of Pennsylvania


For more information, please click here

Contact: Hugo FitzGerald
Phone: 215 573 4307

Copyright © University of Pennsylvania

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Nanometrics Announces Upcoming Investor Events November 18th, 2015

Harris & Harris Group Portfolio Company, D-Wave Systems, Announces Multi-Year Agreement With Lockheed Martin November 16th, 2015

Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA November 16th, 2015

Harris & Harris Group Portfolio Company, D-Wave Systems, Announces the Sale of Its Latest Quantum Computer to Los Alamos National Laboratory November 11th, 2015


Nanoparticles simplify DNA identification and quantification November 27th, 2015

Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015

Electric fields remove nanoparticles from blood with ease November 24th, 2015

Production of Nanocapsules Containing Omega-3 Powder in Iran November 24th, 2015


Overtaking science fiction with physics: 33-year-old physicist at the University of Kaiserslautern receives 1.5 million euros of EU funding November 29th, 2015

'Material universe' yields surprising new particle November 28th, 2015

Iranian Scientists Discover New Catalyst to Remove Pharmaceutical Compounds from Wastewater November 28th, 2015

RAMAN Spectrometry Makes Characterization of Various Nanostructures Possible November 28th, 2015

Human Interest/Art

Bionic liver micro-organs explain off-target toxicity of acetaminophen (Tylenol): Israeli-German partnership aims to replace animal experiments with advanced liver-on-chip devices August 17th, 2015

Omni Nano and Time Warner Cable Partner to Provide Nanotechnology Education to the Boys & Girls Clubs of Los Angeles: A $10,000 Donation to Benefit Youth of Los Angeles County's Boys & Girls Clubs August 4th, 2015

Kalam: versatility personified August 1st, 2015

Pakistani Students Who Survived Terror Attack to Attend Weeklong “NanoDiscovery Institute” at SUNY Poly CNSE in Albany July 29th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic